The DG10S478 Variant in the TCF7L2 Gene is not Associated with Microvascular Complications in Type 2 Diabetes

Abstract

Objective: The DG10S478 variant in the transcription factor 7-like 2 (TCF7L2) gene is a tetranucleotide repeat with six alleles. Alleles 0, 8 and 12 were found to account for 98% of chromosomes in population based controls. The composite allele X (non zero) has been associated with type 2 diabetes while allele 0 (no insertion) was described as protective. However, no data exist about the influence of DG10S478 variants on manifestation of diabetes and development of diabetic complications.

Methods: 250 patients with type 2 diabetes were tested for the DG10S478 allele X and its association with diabetic complications, age at diagnosis of diabetes and BMI.

Results: Allele 0 was found in 42.4% of the examined patients, 45.2% of the participants were found to be heterozygous and 12.4% homozygous for the composite allele X. The correlation of allele X with the age at diagnosis of diabetes was not significant. There was also no association of allele X with retinopathy, nephropathy or neuropathy. Only the correlation with BMI was statistically significant.

Conclusions: The DG10S478 variant seems to have no influence on manifestation of diabetes and the development of microvascular complications.

TCF7L2 - DG10S478 - retinopathy - nephropathy - neuropathy - type 2 diabetes

References

• 1 Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B, Charpentier G, Pattou F, Stetsyuk V, Scharfmann R, Staels B, Frühbeck G, Froguel P. Transcription factor TCF7L2 genetic study in the French population. Expression in human β-cells and adipose tissue and strong association with type 2 diabetes.  Diabetes. 2006;  55 2903-2908
• 2 Couffinhal T, Dufourcq P, Duplaa C. Beta-catenin nuclear activation: common pathway between Wnt and growth factor signalling in vascular smooth muscle cell proliferation?.  Circ Res. 2006;  99 ((12)) 1287-1289
• 3 Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, Mitchell BD, Shuldiner AR. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish.  Diabetes. 2006;  55 2654-2659
• 4 DCCT Research Group . Factors in the development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetic control and complications trials.  Diabetes. 1988;  37 471-481
• 5 Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines.  Cancer Res. 2000;  60 3872-3879
• 6 Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences.  Behavior Research Methods, Intruments & Computers: in press. 2007; 
• 7 Florez JC, Jablonski KA, Bayley N, Pollin TI, Bakker PIW de, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program.  N Engl J Med. 2006;  20 241-250
• 8 Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.  Nat Genet. 2006;  38 320-323
• 9 Helgason A, Pálsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Schäfer H, Faruque M, Doumatey A, Zhou J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Sigurdsson G, Hebebrand J, Pedersen O, Thorsteinsdottir U, Gulcher JR, Kong A, Rotimi C, Stefánsson K. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution.  Nat Genet. 2007;  39 ((2)) 218-225
• 10 Kiessling A, Ehrhart-Bornstein M. Transcription factor 7-like 2 (TCFL2) - a novel factor involved in pathogenesis of type 2 diabetes. Comment on: Grant et al. Nature Genetics 2006.  Horm Metab Res. 2006;  2 137-138
• 11 Kim KI, Cho HJ, Hahn JY, Kim TY, Park KW, Koo BK, Shin CS, Kim CH, Oh BH, Lee MM, Park YB, Kim HS. Beta-catenin overexpression augments angiogenesis and skeletal muscle regeneration through dual mechanism of vascular endothelial growth factor-mediated endothelial cell proliferation and progenitor cell mobilization.  Arterioscler Thromb Vasc Biol. 2006;  26 ((1)) 91-98
• 12 Lehman DM, Hunt KJ, Leach RJ, Hamlington J, Arya R, Abboud HE, Duggirala R, Blangero J, Goring HH, Stern MP. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans.  Diabetes. 2007;  56 389-393
• 13 Loos RJ, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, Ong KK, O'Rahilly S, Wareham NJ. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population.  Diabetes. 2007;  56 1943-1947
• 14 Lynch M, Kewalramani A. Messenger RNA surveillance and the evolutionary proliferation of introns.  Mol Biol Evol. 2003;  20 563-571
• 15 Marzi C, Huth C, Kolz M, Grallert H, Meisinger C, Wichmann HE, Rathmann W, Herder C, Illig T. Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys.  Horm Metab Res. 2007;  39 46-52
• 16 Miriami E, Sperling R, Sperling J, Motro U. Regulation of splicing: the importance of being translatable.  RNA. 2004;  10 1-4
• 17 Oving IM, Clevers HC. Molecular causes of colon cancer.  Eur J Clin Invest. 2002;  32 448-457
• 18 Parra EJ, Cameron E, Simmonds L, Valladares A, MacKeigue P, Shriver M, Wacher N, Kumate J, Kittles R, Cruz M. Association of TCF7L2 polymorphisms with type 2 diabetes in Mexico City.  Clin Genet. 2007;  71 ((4)) 359-366
• 19 Prunier C, Hocevar BA, Howe PH. Wnt signaling: physiology and pathology.  Growth Factors. 2004;  22 141-150
• 20 Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. Inhibition of adipogenesis by Wnt signaling.  Science. 2000;  289 950-953
• 21 Rudofsky  Jr  G, Isermann B, Schilling T, Schiekofer S, Andrassy M, Schneider JG, Morcos M, Humpert PM, Sayed AA, Witte S, Renn W, Pfohl M, Hamann A, Nosikov V, Schleicher E, Haring HU, Rudofsky G, Ritz E, Nawroth PP, Bierhaus A. A 63 bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2004;  112 135-141
• 22 Schäfer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, T'hart LM, Nijpels G, Haeften TW van, Häring HU, Fritsche A. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.  Diabetologia. 2007;  , Jul 28; [Epub ahead of print]
• 23 Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, Duren WL, Chines PS, Stringham HM, Erdos MR, Valle TT, Tuomilehto J, Bergman RN, Mohlke KL, Collins FS, Boehnke M. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample.  Diabetes. 2006;  55 2649-2653
• 24 Smith U. TCF7L2 and type 2 diabetes-we WNT to know.  Diabetologia. 2007;  50 5-7 , Epub 2006 Nov
• 25 Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta.  J Biol Chem. 2005;  280 1457-1464
• 26 Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, Dam RB van, Hu FB. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S women and men.  Diabetes. 2006;  55 2645-2648

Correspondence